A COST-EFFECTIVENESS ANALYSIS OF ABATACEPT, TOCILIZUMAB, AND TNF-INHIBITOR COMPARED WITH RITUXIMAB AS A SECOND-LINE THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS

被引：0
|
作者：
Huoponen, S. [1 ]
Aaltonen, K. J. [1 ]
Joensuu, J. T. [1 ]
Rutanen, J. [2 ]
Relas, H. [3 ]
Taimen, K. [4 ]
Puolakka, K. [5 ]
Sokka, T. [6 ]
Nordstrom, D. [3 ]
Blom, M. [1 ]
机构：
[1] Univ Helsinki, Helsinki, Finland
[2] Lahti Cent Hosp, Lahti, Finland
[3] Helsinki Univ Cent Hosp, Helsinki, Finland
[4] Turku Univ, Cent Hosp, Turku, Finland
[5] South Karelia Cent Hosp, Lappeenranta, Finland
[6] Jyvaskyla Cent Hosp, Jyvaskyla, Finland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1110
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS43
引用
收藏
页码：A538 / A538
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
    Huoponen, Saara
    Aaltonen, Kalle J.
    Viikinkoski, Jaana
    Rutanen, Jarno
    Relas, Heikki
    Taimen, Kirsi
    Puolakka, Kari
    Nordstrom, Dan
    Blom, Marja
    [J]. PLOS ONE, 2019, 14 (07):
  • [2] COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
    Kobelt, G.
    Lindgren, P.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A548 - A548
  • [3] COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH TNF INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND
    Plisko, R.
    Krzystek, J.
    Rys, P.
    Russel-Szymczyk, M.
    Szkultecka-Debek, M.
    Szamotulska, K.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A544 - A544
  • [4] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Diamantopoulos, Alex
    Finckh, A.
    Huizinga, T.
    Sungher, D. K.
    Sawyer, L.
    Neto, D.
    Dejonckheere, F.
    [J]. PHARMACOECONOMICS, 2014, 32 (08) : 775 - 787
  • [5] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Alex Diamantopoulos
    A. Finckh
    T. Huizinga
    D. K. Sungher
    L. Sawyer
    D. Neto
    F. Dejonckheere
    [J]. PharmacoEconomics, 2014, 32 : 775 - 787
  • [6] Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis
    Lopatina, Elena
    Marshall, Deborah A.
    Coupal, Louis
    Le Lorier, Jacques
    Choquette, Denis
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (01) : 157 - 166
  • [7] ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A223 - A224
  • [8] COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) AFTER THE FAILURE OF A FIRST TNF INHIBITOR IN THE UNITED KINGDOM
    Pericleous, L.
    Lebmeier, M.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A307 - A308
  • [9] Cost-effectiveness of rituximab (Mabthera) compared with abatacept (Orencia) for the treatment of moderate/severe rheumatoid arthritis (RA) in the united kingdom
    Lewis, G.
    Kielhorn, A.
    Diamantopoulos, A.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A249 - A250
  • [10] EFFECTIVENESS OF TNF INHIBITOR VERSUS ABATACEPT FOLLOWING TOCILIZUMAB FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Akiyama, M.
    Kaneko, Y.
    Kondo, H.
    Takeuchi, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 953 - 953
12345